## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.8% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($95.30)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Incyte Sets December Investor Lineup as Pipeline Progress Draws Market Attention**
- Source: MyChesCo | 20251201T005122 | Bullish | Relevance: 99%
- Incyte Corp. (NASDAQ: INCY) will present at two major healthcare investor conferences in early December to discuss pipeline updates and strategic priorities. The biopharmaceutical company aims to highlight its late-stage programs, regulatory milestones, and market opportunities in oncology and autoimmune disease. These presentations are anticipated to draw significant market attention as Incyte navigates a competitive landscape to sustain long-term growth.

**2. Incyte Corp. stock underperforms Monday when compared to competitors**
- Source: MarketWatch | 20251201T170600 | Neutral | Relevance: 99%
-  Incyte Corp. (INCY) stock fell by 2.32% to $102.04 on Monday, significantly underperforming the broader market. This decline occurred during a tough trading session where the S&P 500 Index dropped 0.53% and the Dow Jones Industrial Average fell 0.90%. This marks the second consecutive day of losses for Incyte Corp.

**3. Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)**
- Source: Yahoo Finance | 20251203T213000 | Somewhat-Bullish | Relevance: 99%
- Incyte Corporation announced equity inducement awards granted to its new Executive Vice President and General Counsel, Richard Hoffman, under Nasdaq Listing Rule 5635(c)(4). These awards, approved by the compensation committee, include stock options, restricted stock units, and performance shares, all linked to his continued employment. The grants are intended to incentivize Mr. Hoffman's entry into employment with Incyte.

**4. Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel**
- Source: Yahoo Finance | 20251201T050000 | Bullish | Relevance: 99%
- Incyte has appointed Richard Hoffman as its new Executive Vice President and General Counsel, effective December 1, 2025. Hoffman brings over 20 years of experience in corporate governance and business development, having previously served as a partner at Goodwinâ€™s Life Sciences group. He will be a key member of the Executive Leadership Team, overseeing legal and compliance functions and supporting Incyte's growth and innovation initiatives.

**5. Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding**
- Source: Business Wire | 20251202T142129 | Bullish | Relevance: 98%
- Incyte announced a partnership with supermodel Winnie Harlow for "The Power of Choice" campaign to raise awareness about vitiligo. Harlow, who has lived with vitiligo most of her life, shares her personal journey and encourages others to understand the condition and explore treatment options. The campaign aims to empower individuals with vitiligo to make choices that are right for them, supported by healthcare professionals.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $92 | $86 | +7% |
| 2025-12-08 | Wells Fargo | $116 | $97 | +20% |
| 2025-12-08 | Mizuho | $121 | $90 | +34% |
| 2025-11-24 | Barclays | $115 | $101 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Wells Fargo | main | Overweight |
| 2025-12-08 | Mizuho | up | Outperform |
| 2025-11-24 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.20M) |
| Sells | 13 ($23.25M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.1% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $23M sold (13 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.13 indicates undervaluation relative to growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (4 raises, avg +19%). Insider selling cluster ($23.2M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.7B |
| Beta | 0.81 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.13 |
| Forward P/E | 13.2 |
| Current P/E | 14.9 |
| YoY Growth | 12.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from -0.7% to -3.8% (-3.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.8pp (needs >3.0% for momentum thesis). Underperforming sector by 3.5pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.33x) but short-term weakness (below SMA20). MACD histogram bearish (-0.99), momentum weakening. RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.78% (CS: 12) | Weak |
| RSI_14 | 52.2 | Neutral |
| MACD Histogram | -0.99 | Bearish |
| vs SMA20 | 0.972x | Below |
| vs SMA50 | 1.072x | Above |
| vs SMA200 | 1.331x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $101.50
- **Stop Loss:** $95.30 (6.1% risk)
- **Target:** $107.70 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 153
- **Position Value:** $15,529.50
- **Portfolio %:** 15.53%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite. VIX at 16 is below median, showing calm, but breadth is only moderate and put/call is neutral, suggesting neither strong bullish nor defensive extremes. Key drivers are rising Fed rate-cut odds from soft ADP jobs data, mixed earnings across sectors, and ongoing AI/tech strength offset by caution in cyclicals and banks. Positioning should remain selective and neutral, awaiting more decisive macro or earnings signals.*

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*